Findings
Key considerations include accuracy, precision, sampling frequency, resolution, and data processing. Metadata and communication protocols must ensure reliable and secure data collection.
Sponsors must assess data access, security, and compliance with regulations like 21 CFR Part 11. Clarity on manufacturer and sponsor responsibilities is essential for maintaining data integrity.
Safety risks should be minimized, especially for vulnerable populations. Specifications should ensure that devices pose minimal risks when used solely for data capture.
Human Factors: Acceptability, tolerability, and usability directly impact participant recruitment and adherence. Feasibility studies can help evaluate these factors in target populations.
Operational Considerations: Firmware updates, failure rates, battery life, and customer support must be planned for to avoid disruptions in data collection and participant experience.
Non-Performance Specifications: Cost and customer service must be accounted for, ensuring smooth implementation and user support.

Recommendations
Tailor DHT selection to trial needs, focusing on measurement accuracy, precision, and reliability.
Engage sponsors, technology manufacturers, and patient groups to align specifications with practical and clinical requirements.
Ensure compliance with regulatory standards and implement robust processes for secure data transfer and storage.
Test DHTs for usability, tolerability, and operational reliability in representative populations before full-scale implementation.
Develop clear protocols for managing firmware updates, device malfunctions, and participant support to ensure trial continuity.

Regulatory Considerations
Ensure all data management processes comply with regulatory requirements like 21 CFR Part 11 and align with FDA guidance.
Validate DHTs within the target population to confirm their reliability and relevance for the specific trial context.
Clearly communicate how data will be used and shared to maintain ethical standards and informed consent compliance.
Minimize participant risks by selecting devices with proven safety profiles and addressing potential vulnerabilities during feasibility testing.

Findings
The glossary establishes consistent terminology for digital health technologies, improving clarity in clinical research.
Definitions cover key aspects of digital measurement, including accuracy, precision, and validation.
Data integrity, security, and authentication are emphasized, particularly regarding structured and real-time data.
The glossary distinguishes between raw and processed data, providing clarity on data attribution and authenticity.
It includes terms relevant to both consumer-grade and regulated medical devices, supporting their appropriate use in clinical trials.

Findings
Advantages of MCTs: Investigators highlighted streamlined study operations, remote data capture, and higher-quality, real-time data collection as key benefits. MCTs were also noted for their potential to reduce participant burden by enabling remote participation.
Challenges of MCTs: Investigators reported increased operational challenges, such as device setup, maintenance, and troubleshooting. They also noted time burdens for staff and uncertainties regarding data quality, including potential biases and technical malfunctions.
Support Needs: Investigators emphasized the need for technical support, comprehensive training for staff and participants, and adequate budgetary planning to address additional costs associated with MCTs.
Participant Considerations: While MCTs offer convenience and engagement opportunities for participants, challenges include the intrusiveness of data capture, technology adoption barriers, and potential negative impacts of real-time data access on participant behavior.
Recommendations: Investigators stressed the importance of collaborative relationships between sponsors and sites, user-friendly technology selection, and participant-centric trial designs.

Recommendations
Improve Training and Support: Sponsors should provide hands-on training for staff and participants, including troubleshooting support and device-specific materials.
Plan Budgets Appropriately: Include funds for device procurement, staff time, and technology management in trial budgets.
Enhance Technical Support: Sponsors should establish centralized technical support systems to address technology-related issues during trials.
Select Participant-Friendly Technologies: Prioritize devices that are intuitive, minimally intrusive, and suitable for the target population's needs.
Engage Stakeholders Early: Collaborate with investigators, participants, and sponsors during trial planning to align expectations and address potential challenges.

Regulatory Considerations
Data Security: Ensure data collected by mobile technologies comply with privacy and security regulations, and communicate these measures to IRBs.
Device Validation: Validate devices for the intended trial context to ensure reliability and minimize technical risks.
Participant Communication: Clearly inform participants about how their data will be used and provide transparency regarding data access.

Findings
DMOs offer a novel method to monitor mobility performance in real-world conditions across multiple diseases, but no current gold standard exists for direct comparison.
A 24-month observational clinical study with disease-specific cohorts is considered a valid exploratory step for validating DMOs.
Disease-specific endpoints (e.g., EDSS for MS, FEV1 for COPD) are supported as anchors for evaluating DMOs’ predictive capacity and construct validity.
The Later-Life Function & Disability Instrument (LLFDI) requires additional validation for use as a disease-independent biomarker, especially in younger populations.
Validation of DMOs as surrogate endpoints is contingent upon demonstrating robust correlations with established clinical outcomes in each disease.

Recommendations
Continue using disease-specific endpoints (e.g., EDSS for MS, FEV1 for COPD) to validate DMOs within individual diseases.
Validate the LLFDI tool across diverse age groups and diseases to establish its utility as a disease-independent biomarker.
Explore combining multiple DMOs to enhance predictive capacity where applicable.
Focus on disease-specific biomarkers until sufficient evidence supports the use of DMOs as disease-independent endpoints.
Conduct randomized clinical trials as a follow-up to the observational study to evaluate DMOs’ responsiveness to therapeutic interventions.

Regulatory Considerations
Established endpoints must be used to validate DMOs for consideration as secondary endpoints in regulatory submissions.
Disease-specific validation should be prioritized over disease-independent validation until robust evidence supports the latter.
Provide standardized and regionally consistent criteria for endpoints such as care home admission (PFF) or fall frequency (PD).
Correlate DMOs with widely accepted clinical measures (e.g., FEV1 in COPD) to strengthen regulatory positioning.
Incorporate randomization in future studies to further validate DMOs as surrogate endpoints predictive of clinical outcomes.

Findings
There is a lack of accepted DHT-derived endpoints for labeling claims, with most endpoints categorized as secondary measures.
Barriers include sponsor uncertainty, a burdensome qualification process, and the need for shared standards and data.
Key evidence required includes demonstrating the safety, reliability, and meaningfulness of endpoints in specific trial contexts.
Collaboration among stakeholders, including regulators, patients, and technology providers, is essential for advancing endpoint development.
Engagement with regulatory bodies, such as FDA and EMA, is critical to align endpoints with evidentiary and regulatory standards.

Recommendations
Engage Early and Collaboratively: Engage with regulators, patients, and technology providers early in the process to ensure alignment on trial design and endpoint validation.
Focus on Fit-for-Purpose Validation: Ensure DHTs and endpoints are validated for their intended contexts of use, with evidence supporting their reliability and relevance.
Use Exploratory Endpoints in Early Trials: Include novel endpoints in early-phase trials and observational studies to build evidence for regulatory submission.
Promote Knowledge Sharing: Develop shared databases and resources to standardize data collection and analysis across trials.
Incorporate Meaningful Measures: Align endpoints with patient-reported outcomes and clinical assessments to ensure they capture meaningful health improvements.

Regulatory Considerations
Use tools like the FDA's Critical Path Innovation Meetings (CPIM) to obtain early feedback on endpoint development.
Distinguish between device validation and endpoint validation, ensuring clarity in regulatory submissions.
Provide specific examples of how endpoints and technologies will be used to demonstrate their value and mitigate risks.
Ensure endpoints align with regulatory definitions of clinically meaningful outcomes, such as changes in health status that matter to patients, caregivers, and clinicians.
Address interoperability, privacy, and compliance concerns to meet regulatory and ethical standards.

Findings
Patient-centeredness is a key criterion, with higher importance assigned to endpoints identified by patients as meaningful.
The tool includes predefined weighting criteria to ensure that endpoints addressing unmet needs are prioritized.
A structured rating scale facilitates the comparison of novel endpoints across different therapeutic areas.
Digital measurement technologies, such as wearables and ePROs, are increasingly considered viable novel endpoints.
The tool provides a standardized approach to endpoint selection but requires user input to tailor scores to specific trial needs.

Recommendations
Clinical researchers should use the tool to systematically evaluate novel endpoints before incorporating them into study designs.
Weighting criteria should be adapted based on the specific therapeutic area and patient population to reflect real-world priorities.
Endpoint selection should incorporate regulatory and scientific considerations to ensure alignment with study objectives.
Digital health technologies should be leveraged where appropriate to support novel endpoint validation and implementation.
Stakeholder engagement, including patient advocacy groups, should be integrated into the endpoint selection process.

Regulatory Considerations
Novel endpoints should align with FDA and regulatory body expectations for evidence generation and validation.
The tool does not replace regulatory guidance but can serve as a structured framework for early-phase endpoint assessment.
Sponsors should document endpoint selection rationale in submissions to regulatory agencies.
Digital health endpoints should comply with data integrity and privacy regulations, including HIPAA and GDPR.
Ongoing validation and post-market evidence generation may be required for novel digital endpoints used in pivotal trials.

Findings
There is a wide variability in PA measurement methodologies in existing literature, which complicates comparisons across studies.
The use of digital tools like activity monitors complicates the regulatory process due to non-interchangeability and varying technical and regulatory requirements.
There is a need for standardized procedures to ensure data comparability and integrity.

Recommendations
Implement a standardized methodology for PA data collection and reporting.
Use a standard operating procedure for data collection regarding PA outcomes.
Ensure that activity monitors meet safety, usability, and acceptability criteria for COPD patients.
Encourage widespread adoption of the proposed recommendations to facilitate further research.
Consider device agnosticism while ensuring device sensitivity and accuracy.

Regulatory Considerations
Devices should be device agnostic but must ensure sensitivity, accuracy, and data verification.
Regulatory requirements vary across jurisdictions and need to be met for device approval.
Safety, usability, and acceptability of devices for COPD patients are critical criteria.

Findings
Sponsors must weigh the study benefits of PTs against potential burdens such as usability challenges, frequent reminders, or the need for connectivity and device maintenance.
Factors such as geography, socioeconomics, cultural practices, and technical literacy must be addressed to ensure PT accessibility across diverse patient populations.
Sponsors need to protect patient privacy by adhering to data protection standards and ensuring informed consent materials clearly communicate how data will be used and stored.
Effective maintenance, training, and 24/7 support systems for patients and sites are critical to ensure smooth operation and minimize disruptions.
Providing value to participants, such as progress feedback or gamification elements, can improve the patient experience and adherence.

Recommendations
Design Patient-Centric Materials: Simplify patient-facing materials, tailoring them to low health and technical literacy levels, and ensure patient input is incorporated during the design phase.
Identify and address geographic, socioeconomic, and cultural barriers to technology adoption to ensure inclusivity.
Offer multi-format training for patients and caregivers, provide troubleshooting guides, and ensure 24/7 multilingual technical support.
Safeguard patient data and inform patients of all potential risks associated with PTs. Develop backup plans for device failures or power outages.
Assess how PTs affect daily living, including comfort, usability, and the time required for setup and routine use, to minimize intrusion.

Regulatory Considerations
Ensure adherence to GDPR, HIPAA, and other relevant data protection laws. Clearly communicate privacy and data use details in consent forms.
Validate PTs for safety and suitability in the target population and ensure compliance with regulatory standards for medical devices.
Ensure that consent forms clearly describe PT functionality, benefits, and limitations in accessible language.
Global Adaptability: Account for regional laws, infrastructure limitations, and language requirements to ensure PT compatibility and regulatory compliance across geographies.

Findings
Sufficient resources must be allocated, including infrastructure costs, training, and site reimbursement, to ensure smooth PT deployment.
PTs must be intuitive, validated, and able to withstand technical or environmental challenges to avoid burdening patients and sites.
PTs must comply with data privacy laws (e.g., GDPR, HIPAA) and regulatory standards (e.g., 21 CFR Part 11), and address import restrictions and age limitations.
Scaling PTs requires plans for device maintenance, multilingual support, and consistent availability across geographies and populations.
Sites need adequate training, realistic responsibilities, and clear workflows to avoid overburdening site staff and ensure patient compliance.

Recommendations
Involve key stakeholders (e.g., clinical technologies, regulatory affairs, site relations) early in the planning process to address potential challenges.
Identify risks related to usability, compliance, and data integrity, and establish mitigation strategies before implementation.
Provide tailored training materials for patients and site staff, ensuring clarity and accessibility in multiple formats and languages.
Develop Clear Vendor Contracts: Clearly outline responsibilities for maintenance, data management, and support in vendor contracts to avoid operational ambiguities.
Create Scalability Plans: Address challenges like multilingual support, long-term device maintenance, and cross-region deployment during the initial planning stages.

Regulatory Considerations
Ensure PTs comply with GDPR, HIPAA, and other relevant data protection regulations, particularly in global trials.
Verify if PTs qualify as medical devices and adhere to corresponding regulatory frameworks.
Assess and plan for country-specific import restrictions and data privacy laws to avoid delays.
Validate PTs according to Good Clinical Practice (GCP) guidelines, ensuring reliable data generation and compliance with regulatory standards.
Account for age-related legal restrictions, ensuring PTs are suitable for all intended patient populations.

Findings
Feedback on training for both sites and patients is a critical focus, including its clarity, duration, and accessibility.
Common site challenges include managing logistics, technical troubleshooting, and adapting workflows to accommodate patient-facing technologies.
Patient Experience: The questionnaire captures patient compliance, usability issues, and burden, particularly in remote or decentralized trial setups.
Feedback is collected at three distinct points—early (training), mid-study (technical issues), and post-study (overall impressions)—to address evolving challenges.
Strong communication and timely support from sponsors and vendors are emphasized as critical to resolving issues and maintaining trial integrity.

Recommendations
Incorporate PTSFQ into Trial Protocols: Sponsors should integrate this feedback tool into study plans to systematically capture insights from sites.
Provide comprehensive, multi-format training tailored to diverse learning needs for both site staff and patients.
Establish clear, accessible points of contact for technical and logistical support, ensuring rapid resolution of issues.
Use patient feedback to minimize burden, improve device usability, and ensure compatibility with daily routines.
Regularly review feedback from all PTSFQ sections to identify trends, address issues early, and refine technology use in ongoing and future trials.

Regulatory Considerations
Not provided.

Findings
Scope of Requirements: The requirement applies to NDAs, ANDAs, certain BLAs, and INDs.
Study data must conform to FDA-supported standards listed in the Data Standards Catalog.
Noncommercial INDs (e.g., investigator-sponsored or expanded access INDs) are exempt but may voluntarily comply.
Supported Standards: FDA currently supports standards like SDTM, ADaM, and SEND for tabulation and analysis.
Controlled terminology standards (e.g., MedDRA, CDISC Controlled Terminology) are critical for semantic data interoperability.
Implementation Timelines: New standards become mandatory 24 months after the transition date announced in the Federal Register.
Updates to existing standards are required for studies starting 12 months after their transition date.
Waivers: Waivers may be granted to allow submission using unsupported standard versions, but not for non-standardized data formats.
FDA-Sponsor Interactions: Sponsors should engage with the FDA early in the development process to align on data standardization plans.
Pre-submission technical reviews and Type C meetings can be used to resolve data standardization issues.

Recommendations
Ensure compliance with FDA-supported standards as listed in the Data Standards Catalog.
Begin using the latest supported standards early in the study lifecycle to avoid non-compliance.
Engage with FDA during early-phase development to confirm data standardization plans.
Use tools like the Study Data Technical Conformance Guide for additional implementation support.
Submit waiver requests early if specific standard versions cannot be used.

Regulatory Considerations
Submissions that do not meet the electronic format and data standard requirements may be refused filing (NDAs and BLAs) or refused receipt (ANDAs).
Compliance with standardized formats is mandatory unless explicitly exempted or a waiver is granted.
Updates to supported standards are announced in the Federal Register, with defined implementation periods to allow sponsors to transition.
Sponsors must include critical files like demographic datasets and define.xml files in their submissions to demonstrate standard conformance.

Findings
Digital health technologies (DHTs) enable the creation of novel endpoints that can represent the patient experience more objectively and accurately than traditional measures.
Endpoints derived from DHTs may be more meaningful to patients, healthcare providers, and other stakeholders.
The CTTI pathway for developing novel endpoints is applicable across various chronic conditions, with specific case studies developed for Duchenne Muscular Dystrophy, Diabetes, Parkinson's Disease, and Heart Failure.

Recommendations
A systematic approach should be used to identify and develop key novel endpoints from digital health technologies.
Development should focus on creating measures that are meaningful to patients.
Stakeholders—including patients, regulators, and investigative site personnel—should be engaged early and often in the planning process.
Biostatisticians and data scientists should be involved in key decisions regarding protocol design, data collection, and analysis.
Novel endpoints should be incorporated as exploratory endpoints in existing clinical trials and observational studies to gather evidence

Regulatory Considerations
Developers are advised to engage with regulators like the FDA early and frequently when planning the development of a novel endpoint.
There are established processes for interacting with the FDA, and resources are available to guide developers through these interactions.
The principles of adaptive trial design are the same for studies using mobile technologies as they are for traditional clinical trials.